LYTENAVA Sales Forecast and Market Size Analysis 2020-2034: FDA Setback Shapes LYTENAVA Commercial Path
Outlook Therapeutics' LYTENAVA (bevacizumab gamma) received a Complete Response Letter from the FDA in December 2025, preventing approval for wet AMD treatment in the US. The drug is approved in Europe and positioned as a mid-priced alternative between compounded bevacizumab and premium anti-VEGF therapies, with potential expansion into branch retinal vein occlusion and diabetic macular edema indications.